Form 4: TransMedics CEO buys 8,775 shares at $114

TransMedics CEO Waleed H. Hassanein purchased 8,775 shares at $114 via his revocable trust, bringing total beneficial ownership to 616,433 shares.

Summary

• Waleed H. Hassanein (President & CEO, Director) executed an open-market purchase of 8,775 TransMedics common shares on 2025-11-17.
• Purchase price was $114 per share, implying an aggregate purchase value of approximately $1,000,350 (derived: 8,775 x $114).
• Post-transaction beneficial ownership totals 616,433 shares, consisting of 495,009 shares held indirectly via The Waleed H. Hassanein Revocable Trust and 121,424 shares held directly.
• No derivative securities were reported.
• No Rule 10b5-1(c) trading plan was indicated.

Sentiment

Score: 7

Explanation: CEO’s open-market purchase and higher beneficial ownership are positive sentiment signals without changing fundamentals.

Positives

• Insider open-market purchase by the CEO signals confidence: 8,775 shares at $114.
• Total beneficial ownership increased to 616,433 shares (495,009 indirect via trust; 121,424 direct).
• No dilution to shareholders since this was a secondary market purchase, not an issuance.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

Insider open-market buying by senior executives in medtech is generally viewed positively by investors, signaling confidence in business trajectory. For organ-transplant technology players, where growth and adoption curves can be volatile, CEO purchases often garner attention but do not alter fundamentals.

Comparison to Industry Standards

• Open-market insider purchases by CEOs are less frequent than option exercises in medtech; when disclosed, they are typically interpreted as a constructive signal relative to broader sector norms.
• Compared with peers in specialized transplant technologies (e.g., XVIVO Perfusion, OrganOx), visible insider buying is a supportive sentiment indicator but not a substitute for operating metrics.
• Versus large-cap medtech (e.g., Edwards Lifesciences, Intuitive Surgical), the absolute dollar size is modest and unlikely to shift institutional models absent accompanying fundamentals.

Stakeholder Impact

• Shareholders: Positive sentiment from CEO insider buying; no dilution.
• Employees: Neutral; no operational changes disclosed.
• Customers and suppliers: Neutral; no commercial terms affected.
• Creditors: Neutral; no balance sheet implications indicated.

Key Dates

Recommendation

An insider purchase by the CEO is a constructive signal but, in isolation, does not change the investment case or provide new fundamental data. Maintain a hold pending operational or financial updates.

Keywords

TransMedics, TMDX, insider purchase, Form 4, Waleed Hassanein, CEO buy, beneficial ownership, revocable trust, open market purchase, Rule 10b5-1